177Lu-PSMA-617
Novartis
['prostate']
#cctg @ #asco22 #asco2022 cctg pr.21
a randomized phase ii study of [177lu]lu-psma-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and psma-positive disease (nct04663997) abstract link: 
The Canadian Cancer Trials Group is a cancer clinical trials research cooperative that runs phase I-III trials to test anti-cancer and supportive therapies.